

RECEIVED

NOV 13 2002

TECH CENTER 1600/2900

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/055,143
	Filing Date	01/22/2002
	First Named Inventor	Chapman
	Group Art Unit	1644
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	18242-508 CIP2 (VI-8 CIP2)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
W	A10	3,636,196	1/18/72	Bauer, et al.			
	A11	4,429,045	1/31/84	Bass, et al.			5/10/82
	A12	4,567,042	1/28/86	Acree, et al.			6/7/84
	A13	5,229,012	7/20/93	Pall, et al.			6/24/91
	A14	5,547,576	8/20/96	Onishi, et al.			6/6/93
	A15	5,808,011	9/15/98	Gawryl, et al.			7/1/96
	A16	6,093,564	7/25/00	Budowsky, et al.			1/12/98
	A17	6,099,734	8/8/00	Boggs, et al.			7/8/98
	A18	6,139,878	10/31/00	Summari, et al.			4/27/98
	A19	6,114,108	9/5/02	Budowsky			8/29/95
	A20	6,136,586	10/24/00	Budowsky			5/13/97
	A21	6,150,109	11/21/00	Edson, et al.			1/25/99
	A22	5,891,705	4/6/99	Budowsky, et al.			4/8/97
	A23	6,352,695	5/5/02	Budowsky, et al.			10/3/97
	A24	6,166,187	12/26/00	Prusiner, et al.			5/5/99
	A25	6,197,207	3/6/01	Chapman, et al.			5/21/97
	A26	6,221,614	4/24/01	Prusiner, et al.			1/20/99
	A27	6,251,295	6/26/01	Johnson			1/8/98
	A28	6,369,048	4/9/02	Budowsky, et al.			1/12/98
	A29	6,403,359	1/11/02	Purnal, et al.			9/25/98
W	A30	6,410,219	6/25/02	Cook, et al.			3/30/00

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
W	A31	2002/0034724	3/21/02	Edson, et al.			6/8/01
	A32	2001/0009756	7/26/01	Hei, et al.			7/8/98
	A33	2001/0018179	12/30/01	Hei			7/8/98

Wu Wain

8/18/04



RECEIVED


NOV 13 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
UL	B9	WO 97/07674	Pentose Pharmaceuticals, Inc.	3/6/97			
	B10	WO 98/30327	CERUS Corporation	7/16/98			
	B11	WO 98/45415	Pentose Pharmaceuticals, Inc.	10/15/98			
	B12	WO 99/17802	Pentose Pharmaceuticals, Inc.	4/15/99			
	B13	WO 99/34797	Pentose Pharmaceuticals, Inc.	7/15/99			
	B14	WO 99/34914	Cerus Corporation	7/15/99			
	B15	WO 99/34915	Cerus Corporation	7/15/99			
	B16	WO 00/43048	Common Services Agency	7/21/00			
	B17	WO 00/43782	The Regents of The University of California	7/27/00			
	B18	WO 99/34839	Cerus Corporation	7/15/99			
	B19	WO 00/18412	Pentose Pharmaceuticals, Inc.	4/6/00			
	B20	WO 00/43549	V.I. Technologies, Inc.	7/27/00			
	B21	WO 00/74731	Baxter International, Inc.	12/14/00			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
UL	C22	Mollison et al. (1997). "Blood Transfusion in Clinical Medicine" Tenth Edition, Blackwell Science: 4.
	C23	Brown, et al. (1998). "The Distribution of Infectivity in Blood Components and Plasma Derivatives in Experimental Models of Transmissible Spongiform Encephalopathy" <i>Transfusion</i> 38: 810-816.
	C24	Ackerman, et al. (1998). Abstract: "INACTINE™ - A potent and Selective Method for Inactivating Viruses in Contaminated Blood Products" 25 th Congress of the International Society of Blood Transfusions (ISBT).
	C25	Edson, et al. (1998). Abstract: "INACTINE™ - An Inactivation Technology for Reducing the Viral Infectivity of Plasma-Derived Proteins and Red Blood Cells" IBC 2 nd International Symposium on Viral Clearance.
	C26	Edson, et al. (1998) Abstract S277: "INACTINE™ - A Viral Inactivation Technology for Reducing the Infectivity of Plasma-Derived Proteins" 51st Annual Meeting of the American Association of Blood Banks (AABB), held in Philadelphia, PA, October 31 - November 4, 1998.
	C27	Purmal, et al. (1998). Abstract S279: "INACTINE™ - A Method for Viral Inactivation in Red Blood Cell Concentrate" 51st Annual Meeting of the American Association of Blood Banks (AABB), held in Philadelphia, PA, 1998; Oct. 31 - Nov. 4, 1998.
	C28	Ackerman, et al. (1999). Abstract: "INACTINE™ - A Viral Inactivation Technology for Reducing the Infectivity of Plasma-Derived Proteins" CHI 5 th Annual Conference on Blood Safety & Screening, held in McLean, VA, Feb. 22-24, 1999.
	C29	Edson, et al. (1999). Abstract S496-040C: "Viral Inactivation in Red Blood Cell Concentrates by INACTINE™: Mechanism of Action and Lack of Effect on Red Cell Physiology" 52 nd Annual Meeting of the American Association of Blood Banks (AABB).
	C30	Edson, et al. (1999). Abstract S85-P: "Evaluation of INACTINE™ as a Second Virucidal Step for Solvent Detergent Treated Plasma for Transfusion" 52 nd Annual Meeting of the American Association of Blood Banks (AABB).
	C31	Lazo, et al. (2000). Abstract S141-0401: "Viral Inactivation of U1 Cell-Associated HIV in Red Blood Cell Concentrates Treated by the INACTINE™ Technology." 53 rd Annual Meeting of the American Association of Blood Banks (AABB), held in Washington, DC, November 4-8, 2000.
	C32	Purmal, et al. (2000) Abstract: "Pathogen Inactivated Red Blood Cells Prepared with the INACTINE™ Technology: Effect on Red Cell Physiology and Bacterial Growth" along with associated poster. 53 rd Annual Meeting of the American Association of Blood Banks (AABB), held in Washington, DC, November 4-8, 2000.
	C33	Chapman, J. et al. (2000). Abstract No. 257: "Preclinical Safety Assessment of Red Blood Cells Virally Inactivated by INACTINE™: Lack of Neoantigenicity", along with the associated poster. American Society of Hematology, 42nd Annual Meeting, held in San Francisco, CA, 12/1 - 12/5/00.
	C34	Pereira, M. et al. (2001). Abstract SP175: "Inactivation of Virulent Trypanosoma Cruzi Trypomastigotes by the INACTINE™ Process"; along with the associated poster 54 th Annual AABB Meeting, San Antonio, TX, October 13-17, 2001.
	C35	AuBuchon, J.P. et al. (2001). Abstract S136-040K: "Phase I Clinical Trial of Pathogen-Inactivated Red Blood Cells Using INACTINE™ Chemistry" 54 th Annual AABB Meeting, San Antonio, TX, October 13-17, 2001.

Handwritten signature and date: 8/18/04



OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
W	C36	Purmal, A. et al. (2001). Abstract SP185: "Removal of White Blood Cell and Plasma Proteins from Leukofiltered Red Blood Cell Concentrates by INACTINE™ Pathogen Inactivation", along with the associated poster, 54 th Annual AABB Meeting, San Antonio, TX, October 13-17, 2001.
	C37	Chapman, J. et al. (2001). Abstract SP181: "Lack of Toxicity of PEN110 Treated Red Blood Cells Without PEN110 Removal in New Zealand White Rabbits", along with the associated poster 54 th Annual AABB Meeting, San Antonio, TX, October 13-17, 2001.
	C38	Purmal, et al. (2001). Abstract SP183: "Collection System Equivalency Using the INACTINE™ Process for Pathogen Inactivation: Red Cell Quality assessment" along with the associated poster 54 th Annual AABB Meeting, San Antonio, TX, October 13-17, 2001.
	C39	Zavizion, et al. (2001). Abstract SP180: "Collection System Equivalency Using the INACTINE™ Process for Pathogen Inactivation: Bacterial Inactivation Assessment" along with the associated poster 54 th Annual AABB Meeting, San Antonio, TX, October 13-17, 2001.
	C40	43 rd Annual ASH Meeting, held in Orlando, FL, December 7-11, 2001: Abstract 2268: "High Efficiency Removal of Prion Proteins from Red Cell Concentrates by the INACTINE™ Process", along with the associated poster.
	C41	Popovsky, M.A. (2001). "Frozen and Washed Red Blood Cells: New Approaches and Applications" <i>Transfusion and Apheresis Science</i> 25:193-194.
	C42	Valeri, C.R. et al. (1984). "The 24-Hour Posttransfusion Survival, Oxygen Transport Function, and Residual Hemolysis of Human Outdated-Rejuvenated Red Cell Concentrates After Washing and Storage at 4°C for 24 to 72 Hours" <i>Transfusion</i> 24(4): 323-26.
	C43	Valeri, C.R. et al. (1980). "Viability and Function of Outdated Human Red Blood Cells After Biochemical Modification to Improve Oxygen Transport Function, Freezing, Thawing, Washing, Postthaw Storage at 4°C, Perfusion <i>In Vitro</i> Through a Bubble Oxygenator, and Autotransfusion" <i>Transfusion</i> 20(1): 39-46.
	C44	DeVenuto, F. et al. (1974). "Rejuvenation of Human Red Blood Cells During Liquid Storage" <i>Transfusion</i> 14(4): 338-344.
	C45	Valeri, C.R. et al. (1980). "Therapeutic Effectiveness and Safety of Outdated Human Red Blood Cells Rejuvenated to Restore Oxygen Transport Function to Normal, Frozen for 3 to 4 Years at -80° C, Washed, and Stored at 4°C for 24 Hours Prior to Rapid Infusion" <i>Transfusion</i> 20(2):159-170.
	C46	Valeri, C.R. et al. (1980). "Therapeutic Effectiveness and Safety of Outdated Human Red Blood Cells Rejuvenated to Improve Oxygen Transport Function, Frozen for About 1.5 Years at 80° C, Washed, and Stored at 4° C for About 24 Hours Prior to Rapid Infusion" <i>Transfusion</i> 20 (3): 263-276.
	C47	Tsvetkova, E.A et al. (2001). "Principles of Selective Inactivation of a Viral Genome. Comparative Kinetic Study of Modification of the Viral RNA and Model Protein with Oligoaziridines" <i>Biochemistry (Moscow)</i> 66(8): 875-884. Translated from <i>Biokhimiya</i> 66 (8) 2001:1078-1088.
	C48	Brown, et al. (1998). "A Universal Inactivant for Decontaminating Blood and Biopharmaceutical Products" <i>Biologicals</i> 26: 39-47.
	C49	Burrage, et al. (1999). "Inactivation of Viruses by Aziridines" Brown F, Vyas G (eds). <i>Advances in Transfusion Safety. Dev Biol. Basel, Karger</i> 102: 131-139.
W	C50	Yamamoto, Nobuto (1966). "Mechanism of Inactivation of DNA and RNA Bacteriophages by Alkylating Agents <i>In Vitro</i> " <i>Cancer Research</i> 26 (part 1): 2301-2306.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	8/18/02
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1731004v1

RECEIVED
NOV 13 2002
TECH CENTER 1600/2900

Date of Deposit: April 8, 2002

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/055,143
	Filing Date	01/22/2002
	First Named Inventor	Chapman
	Group Art Unit	
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	18242-508 CIP2 (VI-8 CIP2)

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
UL	A1	4,482,342	11/13/84	Lueptow, Richard M. et al.	494	21	
	A2	4,585,735	04/29/86	Meryman, Harold T. et al.	435	2	
	A3	4,668,214	05/26/87	Reeder, Gary G.	494	37	
	A4	5,250,303	10/05/93	Meryman, Harold T. et al.	424	533	
	A5	5,298,016	03/29/94	Gordon, Lucas S.	609	4	
	A6	5,601,972	02/11/97	Meryman, Harold R.	435	2	
	A7	5,671,135	09/23/97	Jorgensen, Glen et al.	364	181	
	A8	5,769,839	06/23/98	Carmen, Raleigh A. et al.	604	408	
↓	A9	5,906,915	05/25/99	Payrat, Jean-Marc et al.	435	2	


FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
UL	B1	WO 91/04659	American Red Cross	18 April 1991	x
	B2	WO 97/15685	Ernst-Ludwig Winnacker	01 May 1997	x
	B3	WO 97/43649	Ernst-Ludwig Winnacker	20 November 1997	x
	B4	WO 98/21944	New York Blood Center	28 May 1998	x
	B5	WO 98/52629	Zymequist, Inc.	26 November 1998	x
	B6	WO 00/18969	Pentose Pharmaceuticals, Inc.	06 April 2000	x
	B7	WO 00/29849	Wallacoy	25 May 2000	x
↓	B8	WO 00/33653	Haemonetics Corporation	15 June 2000	x

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
UL	C1	Valeri, et al. (2000). "Posttransfusion survival (24-hour) and hemolysis of previously frozen, deglycerolized RBCs after storage at 4°C for up to 14 days in sodium chloride alone or sodium chloride supplemented with additive solutions" <i>Transfusion</i> 40(11):1337-1340.
	C2	Moore, et al. (1993). "In vivo viability studies of two additive solutions in the postthaw preservation of red cells held for 3 weeks at 4°C" <i>Transfusion</i> 33(9): 709-712.
	C3	Houston, et al. (2000). "Transmission of BSE by blood transfusion in sheep" <i>Lancet</i> 356(9234): 999-1000.
↓	C4	Barclay, et al. (1999). "Distribution of cell-associated prion protein in normal adult blood determined by flow cytometry" <i>British Journal of Haematology</i> 107: 804-814.


8/18/04




OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
llw	C5	Civenni, <i>et al.</i> (1998). "In Vitro Incorporation of GPI-Anchored Proteins Into Human Erythrocytes and Their Fate in the Membrane" <i>Blood</i> 91(5): 1784-1792.
	C6	Hornsey, <i>et al.</i> (2000). "Leucofiltration, retention/generation of soluble prion and annexin V and storage of blood components", <i>Transfusion Science</i> 22: 75-76.
	C7	MacGregor, <i>et al.</i> (1999). "Application of a Time-Resolved Fluoroimmunoassay for the Analysis of Normal Prion Protein in Human Blood and Its Components" <i>Vox Sanguinis</i> 77: 88-96.
	C8	Meryman, <i>et al.</i> (1991). "Refrigerated Storage of Washed Red Cells" <i>Vox Sanguinis</i> 60: 88-98.
	C9	Prowse, <i>et al.</i> (1999). "Preliminary assessment of whole-blood, red-cell and platelet-leucodepleting filters for possible induction of prion release by leucocyte fragmentation during room temperature processing" <i>British Journal of Haematology</i> pages 240-247.
	C10	Chapman (2000). "Progress in Improving the Pathogen Safety of Red Cells Concentrates", <i>Vox Sanguinis</i> 78(suppl 2): 203-204.
	C11	Wagner, <i>et al.</i> (1991). "Approaches to the Reduction of Viral Infectivity in Cellular Blood Components and Single Donor Plasma" <i>Transfusion Medicine Reviews</i> 5(1): pp. 18-32.
	C12	Opinion on "The Safety Of Ruminant Blood With Respect To TSE Risks", pp. 2-66, adopted by the Scientific Steering Committee of the European Commission: Health & Consumer Protection Directorate - General, April 13-14, 2000.
	C13	Lazo, <i>et al.</i> (2000). "Screening of Parvovirus B19 by Polymerase Chain Reaction in Human Plasma Mini-Pools used in the Manufacture of Plas+@SD" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: Abstract 244</i> (1 page). San Francisco, CA.
	C14	Purmal, <i>et al.</i> (2000). "Treatment of Baboon Red Cells with the Inactine™ Pathogen Inactivation Technology does not affect their in Vivo Survival or Antigenicity" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: Abstract 255</i> (1 page). San Francisco, CA.
	C15	Purmal, <i>et al.</i> (2000). "Treatment Of Baboon Red Cells With The Inactine™ Pathogen Inactivation Technology Does Not Effect Their In Vivo Survival Or Antigenicity" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: VITEX Poster Presentation</i> (1 page) San Francisco, CA.
	C16	Fast, <i>et al.</i> (2000). "Treatment of Human Leukocytes with Inactine™ Results in Loss of Function and Induction of Apoptosis" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: Abstract 256</i> (1 page) San Francisco, CA.
	C17	Chapman, <i>et al.</i> (2000). "Preclinical Safety Assessment of Red Cells Virally Inactivated by Inactine™: Lack of Neoantigenicity" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: Abstract 257</i> (1 page) San Francisco, CA.
	C18	AuBuchon, <i>et al.</i> (2000). "In Vivo Recovery of Red Blood Cells Virally Inactivated by Inactine™ and Stored for 28 Days" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: Abstract 3538</i> (1 page). San Francisco, CA.
	C19	Davenport, <i>et al.</i> (2000). "Phase IV Study of Plas+@SD: Hepatitis A (HAV) and Parvovirus B19 (B19) Safety Results" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: Abstract 1942</i> (1 page). San Francisco, CA.
↓	C20	"Asahi Chemical's Filter Removes Prions From Blood", <i>The Nikkei Industrial Daily</i> (Tuesday edition) Abstract, January 16, 2001, 1 page.

llw 8/18/04


Express Mail Label No.: EV058075373US
Date of Deposit: April 8, 2002



Page 3 of 3

	C21	Opinion on, "The Implications of the Houston <i>et al.</i> Paper in the <i>Lancet</i> of 16 September 2000 on the Transmission of BSE by Blood Transfusion in Sheep." (The <i>Lancet</i> , Vol. 356, pp. 999-1000; 955-956; 1013), pp. 2-12, adopted by the Scientific Steering Committee of the European Commission: Health & Consumer Protection Directorate - General.
-----------------------------------------------------------------------------------	-----	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------


* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	8/18/04
-----------------------	-----------------------------------------------------------------------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1653279v1



Please type a plus sign (+) in this box



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/055,143
	Filing Date	January 22, 2002
	First Named Inventor	Chapman
	Group Art Unit	1648
	Examiner Name	Ulrike Winkler
	Attorney Docket Number	18242-508 CIP2 (VI-8 CIP2)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
W	A35	4,567,045	01/28/86	Lyons	424	195.1	

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
W	B23	WO	96/39818	CERUS CORPORATION	12/19/96	

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
W	C61	Dzik, S., <i>Infusionstherapie und Transfusionmedizin</i> , 25(5):282-287 (1998).
	C62	Hope, et al., <i>Blood</i> , Abstract #2268 , 98(11 - part 1):542a (2001).
	C63	Manuclidis, et al., <i>Science</i> , 200(4345):1069-1071 (1978).
	C64	International Search Report for PCT/US02/01878, mailing date: October 8, 2003.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	8/18/04
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Express Mail Label No.: EV074974392US
Date of Deposit: April 9, 2003

Page 1 of 2

Please type a plus sign (+) in this box



RECEIVED

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/055,143
	Filing Date	01/22/02
	First Named Inventor	Chapman
	Group Art Unit	1644
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	18242-508 CIP (VI-8 CIP)

APR 14 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
W	A34	3,487,157	12/30/1969	Pierce, et al.			10/31/1968

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
W	B22	SU 1809836	USSR Chem Phys Inst (with English translation of abstract)	04/15/1993	X	

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
W	C51	Amor and Webb (1986). J Med Virol 19: 367-376.
	C52	Budowsky, et al. (1985). Biorg Khim 11: 989-991 (with English Translation of Abstract).
	C53	Budowsky, et al. (1996). Vacc Res 5: 29-39.
	C54	Budowsky (1991). Adv Viro Res 39: 255-290. ✓
	C55	Chapman (2001). Transf Apher Sci 25: 191-192. ✓
	C56	Hassanian (1992). Revue Elev Med Vet Pays Trop 45: 231-234.
	C57	Kasermann, et al. (2001). Anti Res 52: 33-41. ✓
	C58	Lobastov (1983). Probl Virusol Mol Biol Gistol S-kh Zhivotn, ed. Below: 4-6 (with English Translation). ✓
	C59	Snyder, et al. (2001). 43 rd Ann ASH Meeting 2969 (ABSTRACT ONLY): 709a. ✓
W	C60	Zalesska (1988). "Inactivation of viral genome by beta-propiolactone and ethylenimine using the bacteriophage MS-2 as an example" Russian State Library (with English translation). ✓

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Chapman 8/18/04

Express Mail Label No.: EV074974392US
Date of Deposit: April 9, 2003

APR 09 2003

Page 2 of 2

Examiner Signature		Date Considered	8/18/04
-----------------------	-----------------------------------------------------------------------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1782683v1